July 13 , 2005

BioMimetic Pharmaceuticals Strengthens Senior Leadership Team
- Steven N. Hirsch named Executive Vice President Orthopedics and Chief Operating Officer and Earl M. Douglas, Esq. appointed General Counsel -

BioMimetic Pharmaceuticals, Inc. (BMPI) announced today two additions to their senior management team. Steven N. Hirsch has joined the company as Executive Vice President, Orthopedics and Chief Operating Officer. Earl M. Douglas, Esq. has been appointed General Counsel. These two executives bring key complimentary skills to the leadership team at BMPI, a company focused on the development and commercialization of recombinant protein therapeutics for the treatment of musculoskeletal defects and injuries.

Mr. Hirsch joins BioMimetic Pharmaceuticals from Smith & Nephew Orthopaedics, where he was President of their European business. Mr. Douglas recently served as the General Counsel for Spinal Dynamics, Inc.

“We are delighted to have Steve and Earl join the management team at BioMimetic,” commented Samuel E. Lynch, DMD, DMSc, Chairman and Chief Executive Officer of BMPI. “Steve’s background of more than 20 years experience in the orthopedic industry will be invaluable as we expand into a number of orthopedic indications using our pipeline of regenerative product candidates. Earl not only brings broad legal knowledge to the company including a strong background in intellectual property protection, but also has extensive experience in the orthopedics industry. Both of these additions help position us for success with our orthopedic franchise.”

“The results that BMPI has achieved with its Growth factor Enhanced Matrix (GEMTM) based products positions the Company well to take full advantage of the future of the orthopedic industry, which I believe will be focused on biological solutions,” Hirsch stated. “This company is in a great position to be a leader in this area.”

Mr. Hirsch has spent nearly 25 years in the Orthopedics industry, first with Howmedica, where he was VP of Sales and Marketing for their US Orthopedic business. For the past 8 years, he has been with Memphis based Smith & Nephew Orthopaedics in a variety of positions including SVP of Global Marketing, SVP and General Manager of the Reconstructive (Total Joint) Division and most recently, President of their European Business. Mr. Hirsch received a Bachelor of Engineering Science from the Johns Hopkins University and a Master of Science in Industrial Administration from the Kramnert School of Business at Purdue University.

“I am very excited about joining BioMimetic at a time when so much is coming together for the Company, “ said Mr. Douglas, “With my prior experience as General Counsel for an orthopedic medical device company and my background in intellectual property protection, I believe that we have the opportunity to expand BMPI’s already strong proprietary position in orthobiologics.”

Mr. Douglas’ legal career spans nearly 20 years, including a 5 year stint with Smith & Nephew Orthopaedics, where he specialized in intellectual property and commercial contract work. Most recently he was Vice President and General Counsel for Spinal Dynamics, Inc., a Seattle based company acquired by Medtronics, where he had responsibility for all legal matters including intellectual property, contracts and litigation. Mr. Douglas received a Bachelor of Science Degree in Chemical Engineering from the Massachusetts Institute of Technology and a law degree from Columbia University.

About BioMimetic Pharmaceuticals
BioMimetic Pharmaceuticals, Inc. (BMPI) is a private medical products company focused on the development, commercialization, and ultimate marketing of protein-based therapeutics to treat musculoskeletal (e.g., bone, cartilage, ligament and tendon) injuries and defects. The Company’s lead product candidates combine recombinant human platelet-derived growth factor (PDGF-BB) with synthetic or natural scaffolds to stimulate tissue repair. PDGF-BB is a potent stimulator of cells involved in the musculoskeletal system and has been observed to stimulate bone formation in preclinical and clinical studies. Through license agreements, the Company has established a broad patent portfolio protecting its lead product candidates and clinical indications. For further information, visit www.biomimetics.com.

Forward-looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on the current intent and expectations of the management of BioMimetic Pharmaceuticals. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. BioMimetic’s actual results and the timing and outcome of events may differ materially from those expressed in or implied by the forward-looking statements because of risks associated with our unproven preclinical and clinical development activities, regulatory oversight, intellectual property claims, litigation and other risks. Except as required by law, BioMimetic undertakes no obligation to update any forward-looking or other statements in this press release, whether as a result of new information, future events or otherwise.